| Lipids Management |
1 |
1 |
| COVID-19 |
0 |
0.99 |
| Antiviral Agents |
0 |
0.48 |
| Drug Interaction |
0 |
0.97 |
| COVID-19 Treatment |
0 |
0.47 |
| Hypertension |
0 |
0.4 |
| Blood |
0 |
0.38 |
| Heart Failure (HF) |
0 |
0.35 |
| Statins |
0 |
0.29 |
| Thromboembolism |
0 |
0.28 |
| Cardiovascular Risk Management |
0 |
0.98 |
| Chronic Kidney Disease |
0 |
0.21 |
| Renal Failure |
0 |
0.21 |
| Atrial Fibrillation |
0 |
0.2 |
| Electronic Health Record (EHR) |
0 |
0.2 |
| Heart |
0 |
0.19 |
| Hospital |
0 |
0.19 |
| Primary Care |
0 |
0.19 |
| Pulmonary Embolism |
0 |
0.17 |
| Antihypertensive Agents |
0 |
0.16 |
| Biologic Therapy |
0 |
0.14 |
| Renal Disease |
0 |
0.14 |
| Anticoagulation Therapy |
0 |
0.1 |
| Antiplatelet Agent |
0 |
0.1 |
| Cardiovascular disease |
0 |
0.1 |
| Electronic Medical Record |
0 |
0.1 |
| Embolism |
0 |
0.1 |
| Hemorrhage |
0 |
0.1 |
| Immunization |
0 |
0.1 |
| Immunosuppressive Therapy |
0 |
0.1 |
| Investment |
0 |
0.1 |
| Kidney |
0 |
0.1 |
| Liver |
0 |
0.1 |
| Low-Molecular-Weight Heparin |
0 |
0.1 |
| Monoclonal Antibody |
0 |
0.1 |
| Myopathy |
0 |
0.1 |
| PCSK9 |
0 |
0.1 |
| Pharmacodynamics |
0 |
0.1 |
| Pharmacokinetics |
0 |
0.1 |
| Platelet Count |
0 |
0.1 |
| Point-of-Care |
0 |
0.1 |
| Transplantation |
0 |
0.1 |
| Deep Venous Thrombosis |
0 |
0.08 |
| HIV Infection |
0 |
0.08 |
| Toxicology |
0 |
0.08 |